1.Edge S, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, eds. AJCC Cancer Staging Manual. Springer-Verlag. 2010:1–621.
2.Ajani JA, D'Amico TA, Almhanna K, et al. NCCN clinical practice guidelines in oncology. NCCN. 2015.
3.Waddell T, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D. Gastric cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2013;24(suppl 6):vi57–vi63. doi:10.1093/annonc/mdt344.
4. Association JGC. Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer. 2011;14(2):113–123. doi:10.1007/s10120-011-0040-6.
5. Lee KG,Lee HJ,Oh SY,et al.Is There Any Role of Adjuvant Chemotherapy for T3N0M0 or T1N2M0 Gastric Cancer Patients in Stage II in the 7th TNM but Stage I in the 6th TNM System?Ann Surg Oncol 2016;23:1234-1243.DOI:10.1245/s10434-015-4980-7
6. Imamura T, Komatsu S, Ichikawa D, et al. Poor prognostic subgroup in T3N0 stage IIA gastric cancer, suggesting an indication for adjuvant chemotherapy. J Surg Oncol. 2014;111(2):221–225. doi:10.1002/jso.23796.
7.Araki I, Hosoda K, Yamashita K, et al. Prognostic impact of venous invasion in stage IB node-negative gastric cancer. Gastric Cancer. 2014. doi:10.1007/s10120-014-0362-2.
8.Park JH, Ryu M-H, Kim HJ, et al. Risk factors for selection of patients at high risk of recurrence or death after complete surgical resection in stage I gastric cancer. Gastric Cancer. 2015. doi:10.1007/s10120-015-0464-5.
9.Liang W, He J, Shen Y,et al. Impact of Examined Lymph Node Count on Precise Staging and Long-Term Survival of Resected Non-Small-Cell Lung Cancer: A Population Study of the US SEER Database and a Chinese Multi-Institutional Registry. J Clin Oncol. 2017 Apr 10;35(11):1162-1170.
10. Therneau TM, Atkinson EJ. An Introduction to Recursive Partitioning Using the RPART Routine Technical Report 61. Mayo Foundation: Rochester, 1997
11. O’Sullivan B, Huang SH, Su J, Garden AS, Sturgis EM, Dahlstrom K et al. Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S): a multicentre cohort study. Lancet Oncol 2016; 17: 440–451
12.Songun I, Putter H, van de Velde CJ. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol. 2010;11(5):439–49.
13. Wu CW, Hsiung CA, Li AF, et al. Nodal dissection for patients with gastric cancer: a randomised controlled trial. Lancet Oncol. 2006;7(4):309–15.
14. Degiuli M, Sasako M, Ponti A; Italian Gastric Cancer Study Group. Morbidity and mortality in the Italian Gastric Cancer Study Group randomized clinical trial of D1 versus D2 resection for gastric cancer. Br J Surg. 2010;97(5):643–9.
15. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345(10):725–30.
16. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11–20.
17. Ychou M, Boige V, Pignon JP, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011;29(13):1715–21.
18.Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357(18):1810–20.
19. Sasako M, Sakuramoto S, Katai H, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011;29(33):4387–93.
20. Bang YJ, Kim YW, Noh SH, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012;379(9813):315–21
21.Nakajima T, Nashimoto A, Kitamura M, et al. Adjuvant mitomycin and fluorouracil followed by oral uracil plus tegafur in serosa-negative gastric cancer: a randomised trial. Lancet. 1999;354(9175):273–7.
22. Nashimoto A, Nakajima T, Furukawa H, et al. Randomized trial of adjuvant chemotherapy with mitomycin, fluorouracil, and cytosine arabinoside followed by oral fluorouracil in serosanegative gastric cancer: Japan Clinical Oncology Group 9206-1. J Clin Oncol. 2003;21(12):2282–7.
23.Warneke VS, Behrens HM, Hartmann JT, Held H, Becker T, Schwarz NT, et al. Cohort study based on the seventh edition of the TNM classification for gastric cancer: proposal of a new staging system. J Clin Oncol. 2011;29(17):2364–71.
24. Hsu JT, Lin CJ, Sung CM, et al. Prognostic significance of the number of examined lymph nodes in node-negative gastric adenocarcinoma. Eur J Surg Oncol 2013;39:1287-93.
25.Shiraishi N,Inomata M,Osawa N, et al. Early and late recurrence after gastrectomy for gastric carcinoma[J].Cancer,2000,89(2):255.
26. Lorenzon L,Mercantini P,Ferri M,et al.Lymph-node ratio classification strongly correlates with cancer survivals of patients who underwent r0 resection for gastric cancer with more than 15 nodes harvested[J].European surgical research. Europäische chirurgische Forschung. Recherches chirurgicales européennes,2014,53(1-4):1-10.DOI:10.1159/000360937
27. Is retrieval of at least 15 lymph nodes sufficient recommendation in early gastric cancer?[J].Annals of surgical treatment and research,2014,87(4):180-184.DOI:10.4174/astr.2014.87.4.180
28. Saka M, Katai H, Fukagawa T, Nijjar R, Sano T. Recurrence in early gastric cancer with lymph node metastasis. Gastric Cancer. 2008;11(4):214–8
29. Kim AR,Cho J,Hsu YJ,et al.Changes of quality of life in gastric cancer patients after curative resection: a longitudinal cohort study in Korea.Ann Surg 2012;256:1008-1013.DOI:10.1097/SLA.0b013e31827661c9
30. Vickers AJ,Elkin EB.Decision curve analysis:a novel method for evaluating prediction models.Med Decis Making,2006,26: 565- 574.
31.Fitzgerald M,Saville BR.Decision curve analysis[J]. JAMA, 2015, 313(4): 409-410. DOI:10.1001/jama.2015.37.
32.Hernandez JM,Tsalatsanis A,Humphries LA,et al.Defining optimum treatment of patients with pancreatic adenocarcinoma using regret-based decision curve analysis[J].Annals of surgery, 2014, 259(6): 1208-1214. DOI: 10.1097/SLA. 0000000000000310.
33.Wynants L,Timmerman D,Verbakel J,et al.Clinical utility of risk models to refer patients with adnexal masses to specialized oncology care: multicenter external validation using decision curve analysis[J].Clinical cancer research : an official journal of the American Association for Cancer Research, 2017,():.DOI:10.1158/1078-0432.CCR-16-3248
34.Zastrow S,Brookman-May S,Cong TA,et al.Decision curve analysis and external validation of the postoperative Karakiewicz nomogram for renal cell carcinoma based on a large single-center study cohort[J].World journal of urology, 2015,33(3): 381-388.DOI:10.1007/s00345-014-1321-6.